A new sampling device for faecal immunochemical testing: Haemoglobin stability is still an open issue

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 8, 2014, Pages 1203-1209

  Gnatta, Elisa ^a   Zaninotto, Martina ^a   Epifani, Maria Grazia ^a   Padoan, Andrea ^a   Gjini, Romelda ^a   Plebani, Mario ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

colorectal cancer; faecal immunochemical test; faecal occult blood; preservative buffer

Indexed keywords

HEMOGLOBIN;

ANALYTICAL EQUIPMENT; ARTICLE; CONTROLLED STUDY; DIAGNOSIS; FOB GOLD TUBE NG; FOB GOLD TUBE SCREEN; HUMAN; IMMUNOCHEMISTRY; LIMIT OF QUANTITATION; OCCULT BLOOD TEST; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; ROOM TEMPERATURE; SOLUTION AND SOLUBILITY; STORAGE; CHEMISTRY; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; FECES; MASS SCREENING; OCCULT BLOOD; PROCEDURES;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; HUMANS; MASS SCREENING; OCCULT BLOOD;

EID: 84904009077     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-1074     Document Type: Article

References (21)

1. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366-78.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Cappell MS. The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin North Am 2005;89:1-42.
4. Halloran SP, Launoy G, Zappa M, International Agency for Research on Cancer. European guidelines for quality assurance in colorectal screening and diagnosis. First Edition-Faecal occult blood testing. Endoscopy 2012;44(Suppl 3):SE65-87.
5. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol 2008;103:1541-9.
6. Fraser CG. Fecal occult blood tests. Life savers or outdated colorectal screening tools? Clin Lab News 2011;37:8-10.
7. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C, English Bowel Cancer Screening Evaluation Committee. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2012;61:1439-46.
8. Young GP, Fraser CG, Halloran SP, Cole S. Guaiac-based faecal occult blood testing for colorectal cancer screening-An obsolete strategy? Gut 2012;6:959-60.
9. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-8.
10. Van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90.
11. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-25.
12. Fraser CG. A future for faecal haemoglobin measurements in the medical laboratory. Ann Clin Biochem 2012;49:518-26.
13. Brown LF, Fraser CG. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. Ann Clin Biochem 2008;45:604-5.
14. Grazzini G, Ventura L, Zappa M, Ciatto S, Confortini M, Rapi S, et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010;59:1511-5.
15. Young GP, Sinatra MA, St John DJ. Influence of delay in stool sampling on fecal occult blood test sensitivity. Clin Chem 1996;42:1107-8.
16. Fraser CG, Halloran SP, Allison JE, Young GP. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT). Clin Chem Lab Med 2013;20:1-3.
17. Van Rossum LG, van Rijn AF, van Oijen MG, Fockens P, Laheij RJ, Verbeek AL, et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009;125:746-50.
18. Lee CS, O'Gorman P, Walsh P, Qasim A, McNamara D, O'Morain, et al. Immunochemical faecal occult blood tests have superior stability and analytical performance characteristics over guaiac-based tests in a controlled in vitro study. J Clin Pathol 2011;64:524-8.
19. Guittet L, Guillaume E, Levillain R, Beley P, Tichet J, Lantieri O, et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2011;20:1492-501.
20. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55.
21. Fraser CG, Allison JE, Halloran SP, Young GP. A proposal to standardize reporting units for fecal immunochemical tests for haemoglobin. J Natl Cancer Inst 2012;104:810-4.